| Ytd | 281.69% | |
| 1y | 224.57% |
| Open | 59.25 | Prev Close | 59.42 | Low | 57.39 | High | 59.27 | Mkt Cap | 4.20B |
| Vol | 0.00 | Avg Vol | 1.42M | EPS | -1.67 | P/E | -35.20 | Forward P/E | -25.89 |
| Beta | 0.24 | Short Ratio | 4.54 | Inst. Own | 88.49% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-13 | 50-d Avg | 48.71 | 200-d Avg | 33.96 | 1yr Est | 72.22 |
ELVN News
Stifel analyst Dara Azar maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and raises the p
Guggenheim analyst Michael Schmitz maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and lo
Goldman Sachs analyst Salveen Richter maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and
Dimensional Fund Advisors LP lifted its position in shares of Enliven Therapeutics, Inc. (NASDAQ: EL
Enliven Therapeutics (NASDAQ:ELVN) reported quarterly losses of $(0.49) per share which missed the a
Announced positive Phase 1 clinical data for ELVN-001 in CML, demonstrating encouraging ELVN-001 ef
Avidity Partners Management LP increased its stake in Enliven Therapeutics, Inc. (NASDAQ: ELVN) by 1
Goldman Sachs analyst Salveen Richter maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and
HC Wainwright & Co. analyst Robert Burns maintains Enliven Therapeutics (NASDAQ:ELVN) with a
Stifel analyst Dara Azar maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and raises the p
Jones Trading analyst Boris Peaker maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and ra
This Boulder biotech advancing cancer drugs saw a notable insider sale amid strong 1-year stock gain
Orbimed Advisors reported selling 860,123 shares of ELVN on June 22, 2026, generating a transaction
BURLINGAME, Calif., June 15, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company
Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded War
BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company
BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company
Enliven Therapeutics, Inc. (ELVN) Discusses Updated Phase 1 ENABLE Trial Data for ELVN-001 in Previo
US stocks rise with Nasdaq up 150 points. Dow up 0.54%, Nasdaq up 0.63%, S&P 500 up 0.26%. Indus
Stitch Fix (SFIX) reported better-than-expected financial results, causing its shares to jump 15.8%.
Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ: ELVN), a clinical-stage biopharmaceutic
61% overall MMR and 48% MMR achievement by 24 weeks in the 80 mg QD Phase 1b cohort 67% overall MMR
Wall Street analysts changed outlook on top names. Check analyst ratings page for upgrades, downgrad
Stifel analyst Dara Azar initiates coverage on Enliven Therapeutics (NASDAQ:ELVN) with a Buy rati
Enliven will host a webcast conference call on June 11, at 8:30 a.m. ETBURLINGAME, Calif., June 3, 2
Enliven will host a webcast conference call on June 11, at 8:30 a.m. ET BURLINGAME, Calif.
This oncology-focused biotech, advancing kinase inhibitors for cancer, reported a notable insider sa
BOULDER, Colo., May 21, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Na
This biotech specializes in small molecule kinase inhibitors for cancer, with lead drug candidates i
Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Posit
Abstract includes previously reported data: cumulative MMR rate of 47% with 38% of patients achievin
Abstract includes previously reported data: cumulative MMR rate of 47% with 38% of patients achievin
Goldman Sachs analyst Salveen Richter maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and
Phase 1 data update for ELVN-001 expected mid-2026 Initiation of the Phase 3 ENABLE-2 pivotal trial
Helen Louise Collins exercised and sold 40,000 Common Stock shares over March 9–10, 2026, generating
HC Wainwright & Co. analyst Robert Burns maintains Enliven Therapeutics (NASDAQ:ELVN) with a
Mizuho analyst Salim Syed maintains Enliven Therapeutics (NASDAQ:ELVN) with a Outperform and rais
Shares of Enliven Therapeutics, Inc. (NASDAQ: ELVN - Get Free Report) hit a new 52-week high during
Enliven Therapeutics (NASDAQ:ELVN) reported quarterly losses of $(0.48) per share which missed the a
Enliven Therapeutics' stock rose after early trial results showed strong responses and good safe
Cumulative major molecular response (MMR) rate of 69% by 24 weeks, with 53% of patients achieving MM
Rick Fair, a seasoned executive with deep experience developing and commercializing hematology produ
Terns Pharma presented positive data from ongoing CARDINAL trial of TERN-701 in CML patients, showin